Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Zura Bio (Nasdaq: ZURA) granted options to purchase up to 250,200 Class A Ordinary Shares to five newly hired employees on October 26, 2026.
The options have an exercise price of $3.56 per share, equal to the closing share price that day. The Compensation Committee approved the employment inducement awards outside the 2023 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4), subject to the plan and award agreement terms.
The options vest over four years: one-fourth on the first anniversary of the applicable vesting commencement date, with the remainder in equal quarterly installments. Vesting requires continuous service through each vesting date.
Zura Bio (ZURA) reported third-quarter 2026 financial results and kept its tibulizumab Phase 2 clinical study timelines on track. TibuSHIELD in hidradenitis suppurativa completed enrollment with 247 participants, above target; Zura expects initial results in Q4 2026. TibuSURE in systemic sclerosis enrolled 91 participants, also above target, with results expected in H1 2027. The FDA cleared NEXUS-PMR in polymyalgia rheumatica to proceed, and Zura plans to start it by year-end 2026.
Cash and equivalents totaled $187.7 million at September 30; Zura expects this to fund planned operations through at least the end of 2028. Quarterly research and development expenses rose to $19.491 million from $11.948 million, while administrative expenses increased to $9.282 million from $7.571 million. Net loss attributable to ordinary shareholders widened to $25.825 million from $20.037 million, although loss per share narrowed to $0.20 from $0.21.
Zura Bio (Nasdaq: ZURA), a clinical-stage biotech focused on autoimmune and inflammatory diseases, announced its participation in the Cantor Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 9, 2026, at 9:10 a.m. ET, with one-on-one investor meetings the same day. A live webcast and a replay for at least 30 days will be available in the Investors section of Zura Bio’s website under News & Events.
Zura Bio (Nasdaq: ZURA) reported that on August 20, 2026, it granted inducement awards in the form of options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees. The options were approved by the Board’s Compensation Committee and granted outside the 2023 Equity Incentive Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $5.75 per share, equal to the closing price of Zura Bio’s Class A Ordinary Shares on the grant date. Each option vests over four years, with 25% vesting after one year and the remainder vesting in equal quarterly installments, subject to continuous service.
Zura Bio (Nasdaq: ZURA) reported second quarter 2026 results and clinical progress led by tibulizumab (ZB‑106). Enrollment in Phase 2 studies TibuSHIELD in hidradenitis suppurativa and TibuSURE in systemic sclerosis is complete and exceeded initial targets, with 247 and 91 participants randomized, respectively. Topline data are expected in Q4 2026 for TibuSHIELD and H1 2027 for TibuSURE.
Zura selected polymyalgia rheumatica as a third indication for tibulizumab and plans to initiate the NEXUS‑PMR Phase 2 trial by year‑end 2026 after supportive FDA feedback. Cash and cash equivalents were $205.1 million as of June 30, 2026, which the company expects will fund planned operations through at least the end of 2028. Q2 2026 R&D expenses were $20.7 million, G&A expenses were $8.6 million, and net loss was $26.3 million, or $0.21 per share.
Zura Bio (Nasdaq: ZURA) reported key updates on its bispecific antibody tibulizumab, which targets both BAFF and IL-17.
Phase 2 HS trial TibuSHIELD completed enrollment with 247 participants, exceeding targets, with topline data expected Q4 2026. TibuSURE in systemic sclerosis surpassed its 80-participant target, with enrollment completion expected early July and topline data in H1 2027. Zura plans a third Phase 2 indication by year end 2026 and had $225.6 million in cash as of March 31, 2026, expected to fund operations through at least end of 2028.
Zura Bio (Nasdaq: ZURA) granted an inducement option award to its new Chief Business Officer, Muzammil Mustufa, under Nasdaq Listing Rule 5635(c)(4). The option covers up to 600,000 Class A Ordinary Shares at an exercise price of $4.80 per share, vesting over four years.
Zura Bio (Nasdaq: ZURA), a clinical-stage biotech focused on autoimmune and inflammatory diseases, appointed Muzammil Mustufa as Chief Business Officer.
He will lead corporate strategy, business development, commercial planning, and investor relations as Zura advances its bispecific antibody tibulizumab toward key clinical and corporate milestones.
Zura Bio (Nasdaq: ZURA) reported Q1 2026 results and corporate updates. Cash and cash equivalents were $225.6M as of March 31, 2026, expected to fund operations through at least end of 2028. The company completed a February 2026 public offering raising ~$144M gross.
Tibulizumab Phase 2 programs continue: TibuSHIELD (HS) ~225 patients enrolled, topline data expected Q4 2026; TibuSURE (SSc) ~80 patients enrolled, topline data expected H1 2027. R&D and G&A expenses and net loss increased versus Q1 2025.
Zura Bio (Nasdaq: ZURA) announced inducement equity awards granted April 30, 2026: options to purchase 615,160 Class A shares were issued to eight newly hired employees outside the company’s 2023 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $5.08 (closing price on April 30, 2026) and vest over four years with a one‑year cliff and subsequent equal quarterly vesting, subject to continuous service and the Plan and award agreement terms.